信立泰(002294.SZ)：子公司在2025年欧洲肿瘤内科学会年会展示了JK06在I/II期临床试验中的部分剂量递增数据

Core Viewpoint - Salubris Biotherapeutics, a subsidiary of Xinlitai, presented promising preliminary data on JK06 at the 2025 ESMO conference, indicating good safety and efficacy in patients with advanced unresectable tumors, including non-small cell lung cancer and breast cancer [1] Group 1: Clinical Trial Data - The data presented at ESMO included results from 34 patients with advanced refractory solid tumors enrolled in Europe, all of whom had failed standard treatment options [1] - Among the enrolled patients, 83% had received three or more lines of treatment, and 59% had undergone four or more lines of treatment prior to enrollment [1] - Patients in the dose escalation phase received JK06 treatment every three weeks across five dosage levels ranging from 1.5 to 8.0 mg/kg, with 29 patients undergoing tumor clinical efficacy assessments [1]